EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieKohortenstudie

Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study

Tuong Le Trong Huynh, Hien Dieu Tran, Phong Thanh Pham, Nhan Dinh Tran, Nhan Thanh Nguyen, Huyen Doan Thi Bich Cao, Son Ngoc Nguyen, Anh Phuoc Lan Nguyen, Thoai Anh Nguyen, Sang Phu Bui, Trung Quang Le, Toan Hoang Ngo iD und 1 weitere

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70654 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Tuong Le Trong Huynh und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Can Tho Central General Hospital, Can Tho, Vietnam. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Vingroup Innovation Foundation (VINIF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dapagliflozin and empagliflozin are sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) with equivalent Class IA guideline recommendations in heart failure with reduced ejection fraction (HFrEF).

Objectives

To compare the incidence of major adverse cardiovascular events (MACE) between dapagliflozin and empagliflozin in HFrEF patients treated in routine clinical practice.

Methods

This prospective real‐world cohort study enrolled 1231 consecutive HFrEF patients (left ventricular ejection fraction ≤40%) at Can Tho Central General Hospital, Vietnam (March 2023 to March 2026). Patients received dapagliflozin ( n = 622) or empagliflozin ( n = 609) as part of optimized guideline‐directed medical therapy and the primary outcome was MACE.

Results

MACE occurred in 64 patients (10.3%) receiving dapagliflozin and 111 patients (18.2%) receiving empagliflozin. Following propensity score matching and multivariable adjustment, dapagliflozin was associated with significantly lower odds of MACE (adjusted odds ratio [OR] 0.46; 95% confidence interval [CI] [0.30, 0.67]; p < 0.001). Hospitalization for heart failure was significantly lower with dapagliflozin (8.7% vs . 14.9%; adjusted OR 0.52; 95% CI [0.33, 0.80]; p = 0.003). Corrected all‐cause mortality was 13/622 (2.1%) with dapagliflozin and 25/609 (4.1%) with empagliflozin ( p = 0.048). Multivariable logistic regression identified four independent predictors of MACE: New York Heart Association functional class III‐IV (adjusted OR 15.54; 95% CI [9.09, 28.99]; p < 0.001), sedentary lifestyle (adjusted OR 2.11; 95% CI [1.42, 3.37]; p < 0.001), premature cardiovascular disease history (adjusted OR 2.30; 95% CI [1.29, 4.43]; p = 0.007) and dapagliflozin as an independent protective factor (adjusted OR 0.47; 95% CI [0.31, 0.68]; p < 0.001).

Conclusions

In this real‐world prospective Vietnamese HFrEF cohort followed over 36 months, dapagliflozin was associated with significantly lower odds of MACE and HF hospitalization compared with empagliflozin, with robust adjustment for confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsHumansFemaleProspective StudiesMaleAgedStroke VolumeMiddle AgedHospitalizationVietnamTreatment OutcomeCardiovascular Diseases

Stichwörter der Autor:innen

SGLT2 inhibitordapagliflozinempagliflozinguideline‐directed medical therapyheart failure with reduced ejection fractionmajor adverse cardiovascular eventsreal‐world evidence

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinSodium-Glucose Transporter 2 Inhibitorsempagliflozin

Autor:innen und Institutionen

  • Department of Cardiology, Can Tho Central General Hospital, Can Tho, Vietnam.
  • Department of Internal Medicine, Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam.

ORCID-Profile: Toan Hoang Ngo

Förderung

  • Vingroup Innovation Foundation (VINIF)

Zitieren

APA

Huynh, T. L. T., Tran, H. D., Pham, P. T., Tran, N. D., Nguyen, N. T., Cao, H. D. T. B., Nguyen, S. N., Nguyen, A. P. L., Nguyen, T. A., Bui, S. P., Le, T. Q., Ngo, T. H., & Tran, S. K. (2026). Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70654

Vancouver

Huynh TLT, Tran HD, Pham PT, Tran ND, Nguyen NT, Cao HDTB, et al. Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70654

BibTeX
@article{Huynh2026,
  author = {Huynh, Tuong Le Trong and Tran, Hien Dieu and Pham, Phong Thanh and Tran, Nhan Dinh and Nguyen, Nhan Thanh and Cao, Huyen Doan Thi Bich and Nguyen, Son Ngoc and Nguyen, Anh Phuoc Lan and Nguyen, Thoai Anh and Bui, Sang Phu and Le, Trung Quang and Ngo, Toan Hoang and Tran, Son Kim},
  title = {Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70654}
}
Kostenlos starten →